Prospective, Observational Study in Sickle Cell Disease Patients on Crizanlizumab Treatment in Middle East Countries and India

NCT05020873 · clinicaltrials.gov ↗

TERMINATED

Status

44

Enrollment

INDUSTRY

Sponsor class

Stopped sponsor decision

Conditions

Sickle Cell Disease

Interventions

OTHER: Crizanlizumab

Sponsor

Novartis Pharmaceuticals